1. AP10W, a short peptide derived from AP-2 complex subunit mu-A, displays antifungal activities against Candida albicans and Aspergillus fumigatus.
2. AP10W suppresses fungal biofilm formation and reduces pre-established fungal biofilms.
3. AP10W has little toxicity towards mammalian fibroblasts and effectively promotes the healing of wounded skins infected by C. albicans.
The article is generally reliable and trustworthy as it provides evidence for its claims through experiments conducted in vitro and in vivo, as well as providing detailed descriptions of the results obtained from these experiments. The authors also provide a thorough discussion of the potential mechanisms behind the observed effects of AP10W on fungal cells, which further adds to the trustworthiness of the article. Furthermore, the authors declare no conflict of interest, which suggests that their findings are unbiased and not influenced by any external factors.
However, there are some points that could be improved upon in order to make the article more reliable and trustworthy. For example, while the authors discuss potential mechanisms behind the observed effects of AP10W on fungal cells, they do not provide any evidence to support these claims or explore any counterarguments that may exist. Additionally, while they mention that AP10W has little toxicity towards mammalian fibroblasts, they do not provide any evidence to support this claim or discuss any possible risks associated with using this peptide in vivo. Finally, while they mention that AP10W has potential for future development as an antifungal drug, they do not discuss any possible limitations or drawbacks associated with this potential use.